erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
"we were fully aware of the fact that our twins would be the first babies in the world to receive this treatment in utero," corinna said.
.
.
.